Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

Omalizumab and the risk of malignancy: Results from a pooled analysis

(2012) William Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Role of immunmodulators in allergen-specific immunotherapy

(2011) M. V. Kopp   ALLERGY

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

(2011) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Omalizumab: Anti-IgE Therapy in Allergy

(2011) Matthias Volkmar Kopp   CURRENT ALLERGY AND ASTHMA REPORTS

After 6 years with Xolair; a 3-year withdrawal follow-up

(2009) A. Nopp et al.   ALLERGY

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

(2009) Bob Lanier et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

(2009) Wolfgang Kamin et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

(2008) M. V. Kopp et al.   CLINICAL AND EXPERIMENTAL ALLERGY